TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES

• Main Authors: STEPHAN GASSER, CHRISTIAN KLEIN, TANJA FAUTI, JOHANNES SAM, JENNY TOSCA THOM, RALF HOSSE, MOESSNER EKKEHARD, PABLO UMANA, GUY GEORGES, THOMAS HOFER, JEAN-BAPTISTE PIERRE VALLIER
• Format: Patent
• Language: English; Japanese
• Published: 14.02.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

To provide tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.SOLUTION: A bispecific agonistic CD28 antigen binding molecule is characterized by monovalent binding to CD28, comprising (a) one antigen binding domain capable of specific binding to CD28, (b) at least one antigen binding domain capable of specific binding to a tumor-associated antigen, and (c) a Fc domain composed of a first subunit and a second subunit capable of achieving stable association comprising one or more amino acid substitutions that reduce binding affinity of the antigen binding molecule to an Fc receptor and/or an effector function.SELECTED DRAWING: None 【課題】ＣＤ２８への一価結合を特徴とする腫瘍標的化二重特異性アゴニスト抗原結合分子、それらの製造方法、これらの抗体を含有する薬学的組成物、及びそれらを使用する方法を提供する。【解決手段】ＣＤ２８への一価結合を特徴とする二重特異性アゴニストＣＤ２８抗原結合分子であって、（ａ）ＣＤ２８に特異的に結合可能な１つの抗原結合ドメインと、（ｂ）腫瘍関連抗原に特異的に結合可能な少なくとも１つの抗原結合ドメインと、（ｃ）Ｆｃ受容体に対する抗原結合分子の結合親和性及び／又はエフェクター機能を低下させる１つ以上のアミノ酸置換を含む安定な会合が可能な第１のサブユニット及び第２のサブユニットで構成されるＦｃドメインと、を含む、二重特異性アゴニストＣＤ２８抗原結合分子を提供する。【選択図】なし